Exploiting Radiation Immunostimulatory Effects to Improve Glioblastoma Outcome

Overview

Journal Neuro Oncol

Publisher Oxford University Press

Specialties Neurology
Oncology

Date 2022 Oct 14

PMID 36239313

Authors

Hala Awada

Francois Paris

Claire Pecqueur

Affiliations

Soon will be listed here.

Abstract

Cancer treatment protocols depend on tumor type, localization, grade, and patient. Despite aggressive treatments, median survival of patients with Glioblastoma (GBM), the most common primary brain tumor in adults, does not exceed 18 months, and all patients eventually relapse. Thus, novel therapeutic approaches are urgently needed. Radiotherapy (RT) induces a multitude of alterations within the tumor ecosystem, ultimately modifying the degree of tumor immunogenicity at GBM relapse. The present manuscript reviews the diverse effects of RT radiotherapy on tumors, with a special focus on its immunomodulatory impact to finally discuss how RT could be exploited in GBM treatment through immunotherapy targeting. Indeed, while further experimental and clinical studies are definitively required to successfully translate preclinical results in clinical trials, current studies highlight the therapeutic potential of immunotherapy to uncover novel avenues to fight GBM.

Citing Articles

Targeting CEA in metastatic triple negative breast cancer with image-guided radiation followed by Fab-mediated chimeric antigen receptor (CAR) T-cell therapy.

Aniogo E, Kujawski M, Awuah D, Cha S, Espinosa R, Hui S Front Immunol. 2025; 15:1499471.

PMID: 39759518 PMC: 11695362. DOI: 10.3389/fimmu.2024.1499471.

Multidimensional analysis of matched primary and recurrent glioblastoma identifies contributors to tumor recurrence influencing time to relapse.

Shekarian T, Ritz M, Hogan S, Martins T, Schmassmann P, Gerber A J Neuropathol Exp Neurol. 2024; 84(1):45-58.

PMID: 39423857 PMC: 11659594. DOI: 10.1093/jnen/nlae108.

Barriers to T Cell Functionality in the Glioblastoma Microenvironment.

Nader N, Frederico S, Miller T, Huq S, Zhang X, Kohanbash G Cancers (Basel). 2024; 16(19).

PMID: 39409893 PMC: 11476085. DOI: 10.3390/cancers16193273.

Immunotherapy for glioblastoma: current state, challenges, and future perspectives.

Liu Y, Zhou F, Ali H, Lathia J, Chen P Cell Mol Immunol. 2024; 21(12):1354-1375.

PMID: 39406966 PMC: 11607068. DOI: 10.1038/s41423-024-01226-x.

PD-1 inhibitor plus concurrent chemoradiotherapy for high-risk locally advanced cervical cancer.

Wang C, Liu L, Li X, Lei J, Li Y, Shen Z Future Oncol. 2024; 20(20):1415-1426.

PMID: 38861299 PMC: 11376421. DOI: 10.1080/14796694.2024.2342241.

References

Sato H, Demaria S, Ohno T . The role of radiotherapy in the age of immunotherapy. Jpn J Clin Oncol. 2021; 51(4):513-522. PMC: 8012351. DOI: 10.1093/jjco/hyaa268. View

Serrano-Del Valle A, Anel A, Naval J, Marzo I . Immunogenic Cell Death and Immunotherapy of Multiple Myeloma. Front Cell Dev Biol. 2019; 7:50. PMC: 6476910. DOI: 10.3389/fcell.2019.00050. View

Bhat K, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F . Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. Cancer Cell. 2013; 24(3):331-46. PMC: 3817560. DOI: 10.1016/j.ccr.2013.08.001. View

Chauvin C, Joalland N, Perroteau J, Jarry U, Lafrance L, Willem C . NKG2D Controls Natural Reactivity of Vγ9Vδ2 T Lymphocytes against Mesenchymal Glioblastoma Cells. Clin Cancer Res. 2019; 25(23):7218-7228. DOI: 10.1158/1078-0432.CCR-19-0375. View

Ager C, Zhang H, Wei Z, Jones P, Curran M, Di Francesco M . Discovery of IACS-8803 and IACS-8779, potent agonists of stimulator of interferon genes (STING) with robust systemic antitumor efficacy. Bioorg Med Chem Lett. 2019; 29(20):126640. PMC: 6993876. DOI: 10.1016/j.bmcl.2019.126640. View

Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-60. DOI: 10.1038/nature05236. View

CHAKRAVARTY P, Alfieri A, Thomas E, Beri V, Tanaka K, Vikram B . Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer. Cancer Res. 2000; 59(24):6028-32. View

Scartoni D, Amelio D, Palumbo P, Giacomelli I, Amichetti M . Proton therapy re-irradiation preserves health-related quality of life in large recurrent glioblastoma. J Cancer Res Clin Oncol. 2020; 146(6):1615-1622. DOI: 10.1007/s00432-020-03187-w. View

Chen Y, Song Y, Du W, Gong L, Chang H, Zou Z . Tumor-associated macrophages: an accomplice in solid tumor progression. J Biomed Sci. 2019; 26(1):78. PMC: 6800990. DOI: 10.1186/s12929-019-0568-z. View

10.

Corrales L, Glickman L, McWhirter S, Kanne D, Sivick K, Katibah G . Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep. 2015; 11(7):1018-30. PMC: 4440852. DOI: 10.1016/j.celrep.2015.04.031. View

11.

Gerber D, Chan T . Recent advances in radiation therapy. Am Fam Physician. 2008; 78(11):1254-62. View

12.

Zeng J, See A, Phallen J, Jackson C, Belcaid Z, Ruzevick J . Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys. 2013; 86(2):343-9. PMC: 3963403. DOI: 10.1016/j.ijrobp.2012.12.025. View

13.

Montay-Gruel P, Acharya M, Goncalves Jorge P, Petit B, Petridis I, Fuchs P . Hypofractionated FLASH-RT as an Effective Treatment against Glioblastoma that Reduces Neurocognitive Side Effects in Mice. Clin Cancer Res. 2020; 27(3):775-784. PMC: 7854480. DOI: 10.1158/1078-0432.CCR-20-0894. View

14.

Schmitt M, Company C, Dramaretska Y, Barozzi I, Gohrig A, Kertalli S . Phenotypic Mapping of Pathologic Cross-Talk between Glioblastoma and Innate Immune Cells by Synthetic Genetic Tracing. Cancer Discov. 2020; 11(3):754-777. PMC: 7611210. DOI: 10.1158/2159-8290.CD-20-0219. View

15.

Patel M, Kim J, Theodros D, Tam A, Velarde E, Kochel C . Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma. J Immunother Cancer. 2016; 4:28. PMC: 4869343. DOI: 10.1186/s40425-016-0132-2. View

16.

Kickingereder P, Hamisch C, Suchorska B, Galldiks N, Visser-Vandewalle V, Goldbrunner R . Low-dose rate stereotactic iodine-125 brachytherapy for the treatment of inoperable primary and recurrent glioblastoma: single-center experience with 201 cases. J Neurooncol. 2014; 120(3):615-23. DOI: 10.1007/s11060-014-1595-y. View

17.

Kim J, Patel M, Mangraviti A, Kim E, Theodros D, Velarde E . Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas. Clin Cancer Res. 2016; 23(1):124-136. PMC: 5735836. DOI: 10.1158/1078-0432.CCR-15-1535. View

18.

Yamazaki T, Hannani D, Poirier-Colame V, Ladoire S, Locher C, Sistigu A . Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. Cell Death Differ. 2013; 21(1):69-78. PMC: 3857617. DOI: 10.1038/cdd.2013.72. View

19.

Boothe D, Young R, Yamada Y, Prager A, Chan T, Beal K . Bevacizumab as a treatment for radiation necrosis of brain metastases post stereotactic radiosurgery. Neuro Oncol. 2013; 15(9):1257-63. PMC: 3748921. DOI: 10.1093/neuonc/not085. View

20.

Asaithamby A, Hu B, Chen D . Unrepaired clustered DNA lesions induce chromosome breakage in human cells. Proc Natl Acad Sci U S A. 2011; 108(20):8293-8. PMC: 3100920. DOI: 10.1073/pnas.1016045108. View